Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
The Form 8-K was filed in connection with events occurring on May 5, 2023. Aprea Therapeutics, Inc. is a biotechnology company whose common stock trades on Nasdaq under the symbol APRE. The filing reports a board appointment and related equity compensation; it does not provide quarterly or annual financial results.
Key Financial Metrics and Capital Structure
- The filing does not provide revenue, profit or loss, cash flow, operating margin, debt, liquidity, cash balance, or other financial metrics.
- The filing does not disclose changes in the company’s capital structure beyond the grant of a stock option described below.
Material Changes and Corporate Governance
- Effective May 5, 2023, the board increased from eight to nine directors.
- Gabriela Gruia, M.D., was appointed as a Class II director to serve until the 2024 annual meeting of stockholders or until her earlier resignation or removal.
- Dr. Gruia will not serve on any board committee.
- Dr. Gruia has more than 25 years of oncology drug-development and regulatory experience, including senior leadership at Novartis Oncology and Ichnos Sciences. She also serves on the boards of TSCAN Therapeutics, Tessa Therapeutics Ltd., and Molecular Templates, Inc.
Compensation, Outlook, Risks and Unusual Items
- On May 5, 2023, Dr. Gruia received an option to purchase 12,500 shares of common stock at an exercise price of $3.88 per share, equal to the Nasdaq closing price on the grant date.
- The option vests in full on the first anniversary of the grant date, subject to continuous service.
- The filing states that there are no arrangements or understandings regarding Dr. Gruia’s selection, no applicable family relationships, and no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.
- No financial guidance, operating outlook, contingencies, or material business risks are disclosed in the filing.
- The filing references a press release dated May 8, 2023, although the report identifies May 5, 2023 as the date of the reported event.
Investor Verification Checklist
- Verify the effective date, vesting terms, and exercise price of the 12,500-share director option.
- Review the May 8, 2023 press release attached as Exhibit 99.1.
- Assess Dr. Gruia’s outside board memberships and potential time-commitment or governance considerations.
- Consult the company’s latest periodic filing for financial condition, cash runway, operating results, debt, and clinical-development risks, none of which are provided here.